23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ARCUS BIOSCIENCES INC. › 2023-2024

ARCUS BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ARCUS BIOSCIENCES INC.’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 216Asset managers, any item
  • 1,453Fund votes
  • June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 5 items on ARCUS BIOSCIENCES INC.’s Form 8-K, filed June 6, 2024: 5 passed (calculated).

Dissent

Significant dissent: 1 director (20.0% against).

Notable dissent: 2 directors (14.0%, 13.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARCUS BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARCUS BIOSCIENCES INC.

These tallies are ARCUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARCUS BIOSCIENCES INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Kathryn Falberg 66,352,943---- 10,783,2158,822,193 86%Passed (calculated)—
Elect Director: Linda Higgins 61,694,808---- 15,441,3508,822,193 80%Passed (calculated)—
Elect Director: Terry Rosen 67,130,968---- 10,005,1908,822,193 87%Passed (calculated)—
2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 84,330,5861,242,487385,278 ---- 99%Passed (calculated)—
3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement 74,230,2762,863,26042,662 --8,822,193 96%Passed (calculated)—

Source: ARCUS BIOSCIENCES INC., Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.

How asset managers voted at the ARCUS BIOSCIENCES INC. 2023-2024 meeting

216 asset managers disclosed a vote on at least one ARCUS BIOSCIENCES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Kathryn Falberg

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%
FOR: 66,352,943WITHHELD: 10,783,215
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: Election of Directors: Kathryn Falberg

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kathryn Falberg”): 66,352,943 for, 10,783,215 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 20,673,016 for, 3,669,665 withheld.

FORWITHHOLD
FOR: 20,673,016WITHHOLD: 3,669,665
Largest asset managers voting on “Election of Directors: Kathryn Falberg” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,806,9460 037,382For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street3,475,3330 050,039For
Dimensional00 01,184,566Withhold
AB DISCOVERY GROWTH FUND, INC.00 0551,175Withhold
Charles Schwab468,7380 00For
Delaware/Macquarie00 0379,100Withhold
Equitable82,9990 0253,908Mixed
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust00 0175,280Withhold
Columbia Threadneedle155,7870 00For
Victory Capital00 0139,727Withhold
Jackson National00 0136,438Withhold
TIAA125,2900 00For
ALPS ETF Trust00 064,090Withhold
BNY Mellon00 062,055Withhold
ProShares00 061,739Withhold
Principal00 060,715Withhold
Invesco58,0860 00For
American Century00 057,898Withhold
Prudential/PGIM56,2230 00For
MFS00 056,174Withhold
Lincoln Financial44,4000 08,738Mixed
Thrivent00 046,429Withhold

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Elect Director: Linda Higgins

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 61,694,808WITHHELD: 15,441,350
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: Election of Directors: Linda Higgins, Ph.D.

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Linda Higgins”): 61,694,808 for, 15,441,350 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 17,051,197 for, 7,291,484 withheld.

FORWITHHOLD
FOR: 17,051,197WITHHOLD: 7,291,484
Largest asset managers voting on “Election of Directors: Linda Higgins, Ph.D.” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,806,9460 037,382For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street35,9430 03,489,429Withhold
Dimensional00 01,184,566Withhold
AB DISCOVERY GROWTH FUND, INC.00 0551,175Withhold
Charles Schwab468,7380 00For
Delaware/Macquarie00 0379,100Withhold
Equitable82,9990 0253,908Mixed
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust00 0175,280Withhold
Columbia Threadneedle155,7870 00For
Victory Capital00 0139,727Withhold
Jackson National00 0136,438Withhold
TIAA125,2900 00For
ALPS ETF Trust00 064,090Withhold
BNY Mellon00 062,055Withhold
ProShares00 061,739Withhold
Principal00 060,715Withhold
Invesco00 058,086Withhold
American Century00 057,898Withhold
Prudential/PGIM00 056,223Withhold
MFS00 056,174Withhold
Lincoln Financial00 053,138Withhold
Thrivent00 046,429Withhold

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Elect Director: Terry Rosen

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 67,130,968WITHHELD: 10,005,190
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: Election of Directors: Terry Rosen, Ph.D.

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Terry Rosen”): 67,130,968 for, 10,005,190 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 21,500,622 for, 2,842,059 withheld.

FOR
FOR: 21,500,622WITHHOLD: 2,842,059
Largest asset managers voting on “Election of Directors: Terry Rosen, Ph.D.” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,843,0230 01,305For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street3,475,3330 050,039For
Dimensional00 01,184,566Withhold
AB DISCOVERY GROWTH FUND, INC.551,1750 00For
Charles Schwab468,7380 00For
Delaware/Macquarie00 0379,100Withhold
Equitable336,9070 00For
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust00 0175,280Withhold
Columbia Threadneedle155,7870 00For
Victory Capital00 0139,727Withhold
Jackson National00 0136,438Withhold
TIAA125,2900 00For
ALPS ETF Trust00 064,090Withhold
BNY Mellon00 062,055Withhold
ProShares00 061,739Withhold
Principal00 060,715Withhold
Invesco58,0860 00For
American Century00 057,898Withhold
Prudential/PGIM00 056,223Withhold
MFS56,1740 00For
Lincoln Financial44,4000 08,738Mixed
Thrivent00 046,429Withhold

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the…

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 74,230,276AGAINST: 2,863,260

Prior year: 96.0% for (June 15, 2023 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 216 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.

ARCUS BIOSCIENCES INC.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 74,230,276 for, 2,863,260 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 77 asset managers voting on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclose” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,844,3280 00For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street3,510,91814,454 00For
Dimensional1,184,5660 00For
AB DISCOVERY GROWTH FUND, INC.551,1750 00For
Charles Schwab468,7380 00For
Delaware/Macquarie379,1000 00For
Equitable336,9070 00For
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust175,2800 00For
Columbia Threadneedle155,7870 00For
Victory Capital139,7270 00For
Jackson National136,4380 00For
TIAA125,2900 00For
ALPS ETF Trust64,0900 00For
BNY Mellon62,0550 00For
ProShares61,7390 00For
Principal60,7150 00For
Invesco058,086 00Against
American Century057,898 00Against
Prudential/PGIM56,2230 00For
MFS056,174 00Against
Lincoln Financial53,1380 00For
Thrivent46,4290 00For

Fund voting reports, all 77 managers: 23,981,570 for, 350,897 against, 10,214 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 162 asset managers voting on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclose” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity4,708,6310 00For
State Street4,484,50730,622 00For
Woodline Partners LP2,498,9940 00For
Point721,759,1010 00For
BlackRock1,327,5367,194 00For
GEODE CAPITAL MANAGEMENT, LLC1,151,0100 00For
AMERIPRISE FINANCIAL INC1,053,1520 00For
AllianceBernstein990,7990 00For
SUVRETTA CAPITAL MANAGEMENT, LLC957,2990 00For
Decheng Capital LLC869,7900 00For
BNP Paribas Asset Management Holding S.A.0732,497 00Against
Laurion Capital Management LP502,1230 00For
Charles Schwab493,8230 00For
Northern Trust415,7642,016 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST379,1000 00For
PRINCIPAL GLOBAL INVESTORS288,3920 00For
MELLON INVESTMENTS Corp283,7460 00For
NORDEA INVESTMENT MANAGEMENT AB0259,372 00Against
UBS19233,242 00Against
DAFNA Capital Management LLC231,7150 00For
Two Sigma223,0440 00For
Granahan Investment Management, LLC213,0230 00For
PLATINUM INVESTMENT MANAGEMENT LTD204,3980 00For
PANAGORA ASSET MANAGEMENT INC179,6750 00For
Dimensional176,5380 00For

Institutional-manager reports, all 162 managers: 25,065,027 for, 2,033,215 against, 175 abstained, 2,930 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 84,330,586AGAINST: 1,242,487

Prior year: 98.3% for (June 15, 2023 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

ARCUS BIOSCIENCES INC.’s own tally for this item (“2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December”): 84,330,586 for, 1,242,487 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 23,785,827 for, 546,640 against, 10,214 abstained.

FOR
FOR: 23,785,827AGAINST: 546,640ABSTAIN: 10,214
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,844,3280 00For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street3,520,0865,286 00For
Dimensional1,184,5660 00For
AB DISCOVERY GROWTH FUND, INC.551,1750 00For
Charles Schwab0468,738 00Against
Delaware/Macquarie379,1000 00For
Equitable336,9070 00For
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust175,2800 00For
Columbia Threadneedle155,7870 00For
Victory Capital139,7270 00For
Jackson National136,4380 00For
TIAA125,2900 00For
ALPS ETF Trust64,0900 00For
BNY Mellon62,0550 00For
ProShares61,7390 00For
Principal60,7150 00For
Invesco58,0860 00For
American Century57,8980 00For
Prudential/PGIM56,2230 00For
MFS56,1740 00For
Lincoln Financial53,1380 00For
Thrivent46,4290 00For

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Largest ARCUS BIOSCIENCES INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 90,900,000 shares outstanding at the time of that meeting.

Fund voting reports: top ARCUS BIOSCIENCES INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 6.43%
2BlackRock 5.76%
3Vanguard 5.16%
4State Street 3.88%
5Dimensional 1.30%
6AB DISCOVERY GROWTH FUND, INC. 0.61%
7Charles Schwab 0.52%
8Delaware/Macquarie 0.42%
9Equitable 0.37%
10MUTUAL FUND SERIES TRUST 0.26%
Institutional-manager reports: top ARCUS BIOSCIENCES INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 5.18%
2State Street 4.97%
3Woodline Partners LP 2.75%
4Point72 1.94%
5BlackRock 1.47%
6GEODE CAPITAL MANAGEMENT, LLC 1.27%
7AMERIPRISE FINANCIAL INC 1.16%
8AllianceBernstein 1.09%
9SUVRETTA CAPITAL MANAGEMENT, LLC 1.05%
10Decheng Capital LLC 0.96%

Reported ARCUS BIOSCIENCES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ARCUS BIOSCIENCES INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Gilead Sciences, Inc.30,061,124 33.07%Proxy statement (DEF 14A), table as of March 1, 2024
BlackRock, Inc.10,035,170 11.04%Proxy statement (DEF 14A), table as of March 1, 2024
Vanguard Group6,629,453 7.29%Form 13F, quarter ended March 31, 2024
State Street4,904,513 5.40%Form 13F, quarter ended March 31, 2024
FMR LLC4,728,782 5.20%Proxy statement (DEF 14A), table as of March 1, 2024
Terry Rosen, Ph.D.3,790,875 4.17%Schedule 13D, filed December 17, 2024
Point721,914,932 2.11%Form 13F, quarter ended March 31, 2024
Dimensional Fund Advisors1,621,409 1.78%Form 13F, quarter ended March 31, 2024
Morgan Stanley1,536,088 1.69%Form 13F, quarter ended March 31, 2024
Juan Carlos Jaen, Ph.D.1,421,141 1.56%Proxy statement (DEF 14A), table as of March 1, 2024

Percentages above are of 90,900,000 shares outstanding, as reported by ARCUS BIOSCIENCES INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ARCUS BIOSCIENCES INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 216 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,453 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARCUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARCUS BIOSCIENCES INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ARCUS BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ARCUS BIOSCIENCES (RCUS) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arcus-biosciences-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.